The recent validation of the α-synuclein seed amplification assay as a biomarker with high
sensitivity and specificity for the diagnosis of Parkinson's disease has formed the backbone …

Neurological disorders are the leading cause of cognitive and physical disability worldwide,
affecting 15% of the global population. Due to the demographics of aging, the prevalence of …

Background Loss‐of‐function mutations in the GBA1 gene are one of the most common
genetic risk factors for onset of Parkinson's disease and subsequent progression (GBA‐PD) …

Abstract Parkinson's disease (PD), being the second largest neurodegenerative disease,
poses challenges in early detection, resulting in a lack of timely treatment options to …

The present review provides a comprehensive examination of the intricate dynamics
between α-synuclein, a protein crucially involved in the pathogenesis of several …

Background To date, no disease modifying therapies are available for Parkinson's disease
(PD). Since PD is the second most prevalent neurodegenerative disorder, there is a high …

There is an urgent need to identify drug targets for disease modification in Parkinson's
Disease (PD). In this mini-review we highlight the reasons genetically defined drug targets …

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by
progressive loss of dopamine neurons and aberrant deposits of alpha-synuclein (a-syn) in …